PURPOSE: Focal adhesion kinase (FAK) plays a critical role in ovarian cancer cell survival and in various steps in the metastatic cascade. Based on encouraging in vitro results with FAK silencing, we examined the in vivo therapeutic potential of this approach using short interfering RNA (siRNA) in the neutral liposome 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC). EXPERIMENTAL DESIGN: Therapy experiments of FAK siRNA with or without docetaxel were done using human ovarian cancer cell lines SKOV3ip1, HeyA8, and HeyA8MDR in nude mice. Additional experiments with a cisplatin-resistant cell line (A2780-CP20) were also done. Assessments of angiogenesis (CD31), cell proliferation (proliferating cell nuclear antigen), and apoptosis (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) were done using immunohistochemical analysis. RESULTS: A single dose of FAK siRNA-DOPC was highly effective in reducing in vivo FAK expression for up to 4 days as assayed by Western blot and immunohistochemical analysis. Therapy experiments were started 1 week after injection of the ovarian cancer cells. Treatment with FAK siRNA-DOPC (150 mug/kg twice weekly) reduced mean tumor weight by 44% to 72% in the three cell lines compared with the control group (Ps < 0.05 for HeyA8, A2780-CP20, and SKOV3ip1). When FAK siRNA-DOPC was combined with docetaxel, there was even greater reduction in mean tumor weight in all models (all Ps < 0.05). Similar results were observed in combination with cisplatin. Treatment with FAK siRNA-DOPC plus docetaxel resulted in decreased microvessel density, decreased expression of vascular endothelial growth factor and matrix metalloproteinase-9, and increased apoptosis of tumor-associated endothelial cells and tumor cells. CONCLUSIONS: Taken together, these findings suggest that FAK siRNA-DOPC plus docetaxel or platinum might be a novel therapeutic approach against ovarian cancer.
PURPOSE:Focal adhesion kinase (FAK) plays a critical role in ovarian cancer cell survival and in various steps in the metastatic cascade. Based on encouraging in vitro results with FAK silencing, we examined the in vivo therapeutic potential of this approach using short interfering RNA (siRNA) in the neutral liposome 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC). EXPERIMENTAL DESIGN: Therapy experiments of FAK siRNA with or without docetaxel were done using humanovarian cancer cell lines SKOV3ip1, HeyA8, and HeyA8MDR in nude mice. Additional experiments with a cisplatin-resistant cell line (A2780-CP20) were also done. Assessments of angiogenesis (CD31), cell proliferation (proliferating cell nuclear antigen), and apoptosis (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) were done using immunohistochemical analysis. RESULTS: A single dose of FAK siRNA-DOPC was highly effective in reducing in vivo FAK expression for up to 4 days as assayed by Western blot and immunohistochemical analysis. Therapy experiments were started 1 week after injection of the ovarian cancer cells. Treatment with FAK siRNA-DOPC (150 mug/kg twice weekly) reduced mean tumor weight by 44% to 72% in the three cell lines compared with the control group (Ps < 0.05 for HeyA8, A2780-CP20, and SKOV3ip1). When FAK siRNA-DOPC was combined with docetaxel, there was even greater reduction in mean tumor weight in all models (all Ps < 0.05). Similar results were observed in combination with cisplatin. Treatment with FAK siRNA-DOPC plus docetaxel resulted in decreased microvessel density, decreased expression of vascular endothelial growth factor and matrix metalloproteinase-9, and increased apoptosis of tumor-associated endothelial cells and tumor cells. CONCLUSIONS: Taken together, these findings suggest that FAK siRNA-DOPC plus docetaxel or platinum might be a novel therapeutic approach against ovarian cancer.
Authors: Robert R Langley; Karen M Ramirez; Rachel Z Tsan; Melissa Van Arsdall; Monique B Nilsson; Isaiah J Fidler Journal: Cancer Res Date: 2003-06-01 Impact factor: 12.701
Authors: Anil K Sood; Jeremy E Coffin; Galen B Schneider; Mavis S Fletcher; Barry R DeYoung; Lynn M Gruman; David M Gershenson; Michael D Schaller; Mary J C Hendrix Journal: Am J Pathol Date: 2004-10 Impact factor: 4.307
Authors: Mark S Duxbury; Hiromichi Ito; Eric Benoit; Michael J Zinner; Stanley W Ashley; Edward E Whang Journal: Biochem Biophys Res Commun Date: 2003-11-21 Impact factor: 3.575
Authors: Robert Cornelison; Zachary C Dobbin; Ashwini A Katre; Dae Hoon Jeong; Yinfeng Zhang; Dongquan Chen; Yuliya Petrova; Danielle C Llaneza; Adam D Steg; Laura Parsons; David A Schneider; Charles N Landen Journal: Clin Cancer Res Date: 2017-08-04 Impact factor: 12.531
Authors: Adam D Steg; Kerri S Bevis; Ashwini A Katre; Angela Ziebarth; Zachary C Dobbin; Ronald D Alvarez; Kui Zhang; Michael Conner; Charles N Landen Journal: Clin Cancer Res Date: 2011-12-05 Impact factor: 12.531
Authors: Hee Dong Han; Lingegowda S Mangala; Jeong Won Lee; Mian M K Shahzad; Hye Sun Kim; Deyu Shen; Eun Ji Nam; Edna M Mora; Rebecca L Stone; Chunhua Lu; Sun Joo Lee; Ju Won Roh; Alpa M Nick; Gabriel Lopez-Berestein; Anil K Sood Journal: Clin Cancer Res Date: 2010-06-10 Impact factor: 12.531
Authors: Pablo E Vivas-Mejia; Cristian Rodriguez-Aguayo; Hee-Dong Han; Mian M K Shahzad; Fatma Valiyeva; Mineko Shibayama; Arturo Chavez-Reyes; Anil K Sood; Gabriel Lopez-Berestein Journal: Clin Cancer Res Date: 2011-04-21 Impact factor: 12.531
Authors: Alpa M Nick; Rebecca L Stone; Guillermo Armaiz-Pena; Bulent Ozpolat; Ibrahim Tekedereli; Whitney S Graybill; Charles N Landen; Gabriel Villares; Pablo Vivas-Mejia; Justin Bottsford-Miller; Hye Sun Kim; Ju-Seog Lee; Soo Mi Kim; Keith A Baggerly; Prahlad T Ram; Michael T Deavers; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood Journal: J Natl Cancer Inst Date: 2011-09-28 Impact factor: 13.506
Authors: Mian M K Shahzad; Yong-Hyun Shin; Koji Matsuo; Chunhua Lu; Masato Nishimura; De-Yo Shen; Yu Kang; Wei Hu; Edna M Mora; Cristian Rodriguez-Aguayo; Arvinder Kapur; Justin Bottsford-Miller; Gabriel Lopez-Berestein; Aleksandar Rajkovic; Anil K Sood Journal: Cancer Lett Date: 2012-07-07 Impact factor: 8.679